54 related articles for article (PubMed ID: 23203543)
1. Synthesis, anti-hypertensive effect of a novel angiotensin II AT1 receptor antagonist and its anti-tumor activity in prostate cancer.
Da YJ; Yuan WD; Zhu LF; Chen ZL
Arzneimittelforschung; 2012 Dec; 62(12):637-43. PubMed ID: 23203543
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
Da YJ; Yuan WD; Xin T; Nie YY; Ye Y; Yan YJ; Liang LS; Chen ZL
Bioorg Med Chem; 2012 Dec; 20(24):7101-11. PubMed ID: 23122933
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of a new angiotensin II receptor antagonist.
Zheng HL; Zhu WB; Wu D; Da YJ; Yan YJ; Bian J; Chen ZL
Drug Res (Stuttg); 2014 Dec; 64(12):656-62. PubMed ID: 24573978
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and pharmacological evaluation of a novel AT1 angiotensin II receptor antagonist with anti-hypertension and anti-tumor effects.
Bao X; Zhu W; Da Y; Zhu L; Qie L; Yan Y; Wang L; Tang H; Chen ZL
Clin Exp Hypertens; 2015; 37(6):490-7. PubMed ID: 25919352
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of new 5-nitro benzimidazole derivatives as AT1 antagonists with anti-hypertension activities.
Zhu W; Da Y; Wu D; Zheng H; Zhu L; Wang L; Yan Y; Chen Z
Bioorg Med Chem; 2014 Apr; 22(7):2294-302. PubMed ID: 24613628
[TBL] [Abstract][Full Text] [Related]
6. Effects of the new angiotensin II type 1 receptor antagonist KRH-594 on several types of experimental hypertension.
Inada Y; Murakami M; Kaido K; Nakao K
Arzneimittelforschung; 1999 Jan; 49(1):13-21. PubMed ID: 10028373
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of new tetrazolyl- and carboxy-biphenylylmethyl-quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists.
Ismail MA; Barker S; Abou el-Ella DA; Abouzid KA; Toubar RA; Todd MH
J Med Chem; 2006 Mar; 49(5):1526-35. PubMed ID: 16509571
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme and angiotensin II receptor subtype 1 inhibitors restitute hypertensive internal anal sphincter in the spontaneously hypertensive rats.
De Godoy MA; Rattan S
J Pharmacol Exp Ther; 2006 Aug; 318(2):725-34. PubMed ID: 16648368
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect.
Nie YY; Da YJ; Zheng H; Yang XX; Jia L; Wen CH; Liang LS; Tian J; Chen ZL
Bioorg Med Chem; 2012 Apr; 20(8):2747-61. PubMed ID: 22410249
[TBL] [Abstract][Full Text] [Related]
10. Characterization of angiotensin II antagonism displayed by Ib, a novel nonpeptide angiotensin AT(1) receptor antagonist.
Wu J; Wang Q; Guo J; Hu Z; Yin Z; Xu J; Wu X
Eur J Pharmacol; 2008 Jul; 589(1-3):220-4. PubMed ID: 18571160
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT1 receptor antagonists.
Wang JL; Zhang J; Zhou ZM; Li ZH; Xue WZ; Xu D; Hao LP; Han XF; Fei F; Liu T; Liang AH
Eur J Med Chem; 2012 Mar; 49():183-90. PubMed ID: 22309912
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models.
Yamamoto S; Hayashi N; Kometani M; Nakao K; Inukai T
Arzneimittelforschung; 1997 May; 47(5):604-12. PubMed ID: 9205773
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists.
Cosentino F; Savoia C; De Paolis P; Francia P; Russo A; Maffei A; Venturelli V; Schiavoni M; Lembo G; Volpe M
Am J Hypertens; 2005 Apr; 18(4 Pt 1):493-9. PubMed ID: 15831358
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological activity of 2-alkylbenzimidazoles bearing a N-phenylpyrrole moiety as novel angiotensin II AT1 receptor antagonists.
Xu JY; Zeng Y; Ran Q; Wei Z; Bi Y; He QH; Wang QJ; Hu S; Zhang J; Tang MY; Hua WY; Wu XM
Bioorg Med Chem Lett; 2007 May; 17(10):2921-6. PubMed ID: 17412584
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment.
Uemura H; Ishiguro H; Kubota Y
Int J Urol; 2008 Jan; 15(1):19-26. PubMed ID: 18184167
[TBL] [Abstract][Full Text] [Related]
16. A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. II: In vivo efficacy and pharmacokinetic studies.
Li L; Zhu Z; Joshi B; Zhang C; Johnson CR; Marnett LJ; Honn KV; Crissman JD; Porter AT; Tang DG
Anticancer Res; 1999; 19(1A):61-9. PubMed ID: 10226525
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor beta1 mediates apoptotic activity of angiotensin II type I receptor blocker on prostate epithelium in vitro.
Zhao Y; Peng J; Zheng L; Yu W; Jin J
Prostate; 2010 Jun; 70(8):899-905. PubMed ID: 20135646
[TBL] [Abstract][Full Text] [Related]
18. AT1 receptor in rostral ventrolateral medulla mediating blunted baroreceptor reflex in spontaneously hypertensive rats.
Gao XY; Zhang F; Han Y; Wang HJ; Zhang Y; Guo R; Zhu GQ
Acta Pharmacol Sin; 2004 Nov; 25(11):1433-8. PubMed ID: 15525464
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist.
Hilditch A; Hunt AA; Travers A; Polley J; Drew GM; Middlemiss D; Judd DB; Ross BC; Robertson MJ
J Pharmacol Exp Ther; 1995 Feb; 272(2):750-7. PubMed ID: 7853190
[TBL] [Abstract][Full Text] [Related]
20. Losartan reduces monocyte chemoattractant protein-1 expression in aortic tissues of 2K1C hypertensive rats.
Xie QY; Sun M; Yang TL; Sun ZL
Int J Cardiol; 2006 Jun; 110(1):60-6. PubMed ID: 16242797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
